10 chapters across the catalog
Analysts suggest that Marty McCary's tenure was marked by significant turnover and mass layoffs of veteran agency staff. A Bloomberg analyst noted that McCary was "very good" to those on the "buy side," implying a cozy relationship with pharmaceutical investors. The hosts question why Robert F. Kennedy Jr. has not been more vocal about the resignation.
Deborah Birx, Armata Pharmaceuticals and Mass Cattle Testing
Dr. Deborah Birx, now representing Armata Pharmaceuticals, called for weekly PCR testing of every dairy cow in the United States to track asymptomatic bird flu spread. The hosts calculate the immense cost of such a program—potentially billions of dollars per week—and suggest it is a strategy to benefit biotech firms and testing manufacturers.
India Vaccination Drive, Bharat Biotech and AstraZeneca
India is preparing for a massive vaccination drive using the AstraZeneca jab and a local version from Bharat Biotech. Despite having four times the U.S. population and significant squalor, India reports half the number of COVID-19 deaths. The country recently conducted nationwide "dry runs" to test health infrastructure, cold storage, and online databases for mass inoculation.
Vivek Ramaswamy's performance in town halls is analyzed as a strategic "stick" or foil for Donald Trump. Ramaswamy has shifted from a biotech CEO to a vocal political figure, often delivering Trump's core messages with a more polished and aggressive rhetorical style.
Show Sign-off, End of Show Mix and Media Montage
The hosts sign off from FEMA Region 6 and Silicon Valley, directing listeners to the No Agenda stream for "Hog Story." The episode concludes with a complex media montage and music mix featuring clips about Chinese balloons, biotech, fentanyl seizures, and the "Agenda 2030" initiative. Credits are given to the mix producers and the "value for value" supporters.
India begins a nationwide vaccine drive using the Oxford-AstraZeneca shot and the indigenous "Covaxin" by Bharat Biotech. The latter has raised alarm bells for being approved before clinical trials were concluded. The hosts question why India's death numbers are so low compared to the U.S. despite its much larger population.
Joe S. Chinaman, newly knighted as Sir Olympus, announced the launch of his biotech startup, PetriBio. The company focuses on developing treatments for aging-related diseases by utilizing peptides and biomolecules from the gut microbiome. He requested "PCR primers and master mix" for the No Agenda roundtable.
A second round of donor thank-yous includes several Eagle Scouts and a mention of "Knobcon," a synthesizer convention in Illinois. The hosts reiterate that the show's lack of corporate advertising allows for honest reporting on the pharmaceutical industry. A "matchmaking" effort is also mentioned to help a biotech professional find employment through the listener network.
FDA Biosimilar Approval, Biotech Drug Pricing
The FDA has approved the first "biosimilar" drug, a low-cost version of the biotech drug Neupogen used for cancer patients. Unlike traditional generics, biosimilars are derived from living organisms; the discussion notes that the lack of transparent pricing for these drugs allows biotech firms to maintain high costs, exemplified by a recent $21 billion company buyout.
Dr. Islam Siddiqui, a former lobbyist for CropLife America, is highlighted as the chief agricultural negotiator for the U.S. government. The hosts point out the conflict of interest in having a representative of the pesticide and biotech industries, including Monsanto, negotiating agricultural policy.
